The purchase price allocation for this acquisition
is shown below:
|
|
|
|
|
|
Fair value of consideration transferred:
|
|
|
|
|
|
Cash
|
|
$ |
6,248 |
|
|
Liability (i)
|
|
|
2,590 |
|
|
|
|
|
|
|
|
|
8,838 |
|
|
|
|
|
|
|
Fair value of previously held interest:
|
|
|
|
|
|
Fair value of previously held interest immediately before
acquisition
|
|
|
3,315 |
|
|
Loss due to fair value remeasurement at acquisition date
|
|
|
(347 |
) |
|
|
|
|
|
|
|
|
2,968 |
|
|
|
|
|
|
|
|
$ |
11,806 |
|
|
|
|
|
|
|
Fair value of net assets acquired:
|
|
|
|
|
|
Cash
|
|
$ |
109 |
|
|
Accounts receivable
|
|
|
51 |
|
|
Prepaid and deposits
|
|
|
29 |
|
|
Inventory
|
|
|
1,194 |
|
|
Biological assets
|
|
|
866 |
|
|
Property and equipment
|
|
|
10,282 |
|
|
Goodwill
|
|
|
1,400 |
|
|
Health Canada license
|
|
|
9,596 |
|
|
Accounts payable and accrued liabilities
|
|
|
(2,860 |
) |
|
Loans payable
|
|
|
(7,461 |
) |
|
Deferred tax liability
|
|
|
(1,400 |
) |
|
|
|
|
|
|
|
$ |
11,806 |
|
|
|
|
|
|
The Company finalized its assessment of the
purchase price allocation during the year ended December 31,
2017. The allocation of the consideration paid remains consistent
with the initial valuation.
| (i) |
During the year ended December 31, 2017, the
full balance of the purchase price liability was repaid by the
Company.
|
|